Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients

Last updated: August 7, 2013
Sponsor: Daewon Pharmaceutical Co., Ltd.
Overall Status: Completed

Phase

3

Condition

Arthritis And Arthritic Pain

Dermatomyositis (Connective Tissue Disease)

Joint Injuries

Treatment

N/A

Clinical Study ID

NCT01781702
DW Plb RA301
  • Ages 18-80
  • All Genders

Study Summary

A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Adult males/Females aged 18~80 years

  2. Patient who are taking NSAIDs for the treatment of rheumatoid arthritis

  3. Patients who belong to ACR functional class 1, 2, 3

Exclusion

Exclusion Criteria:

  1. Patients who belong to ACR functional class 4

  2. Patients who are hypersensitive to clinical trial medicines or excipient

  3. Patients who have experience of Cerebrovascular bleeding, bleeding disorder

Study Design

Total Participants: 120
Study Start date:
October 01, 2010
Estimated Completion Date:
October 31, 2011